Transforming Spine Surgery Through Personalized Solutions
Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time.
Our Core Values
We are committed to three guiding principles:

PATIENT-OBSESSED.
DO WHAT IS RIGHT.
ACHIEVE TOGETHER.
Leadership Team

Mike Cordonnier
Chief Executive Officer
Mike Cordonnier
Chief Executive Officer
Mike is the co-founder and serves as Chief Executive Officer and President of Carlsmed, he also serves as Chairman of the Board of Directors.
Mike has over two decades of experience successfully leading teams in introducing groundbreaking medical technologies. He possesses extensive operational expertise in both private and public companies, having contributed to the success of organizations such as NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems.
Mike holds a Bachelor of Science in Mechanical Engineering from the University of Dayton.

Jodi Allen
Senior Vice President, People and Culture
Jodi Allen
Senior Vice President of People and Culture
Jodi is the Senior Vice President of People and Culture at Carlsmed.
She brings over a decade of experience leading strategic planning and business intelligence across both public and private organizations, most recently at NuVasive.
Jodi holds an MBA from California State University and a Bachelor of Arts in Political Science from the University of Illinois.

Jeff Bertolini
Senior Vice President of Operational Excellence
Jeff Bertolini
Senior Vice President of Operational Excellence
Jeff is the Senior Vice President of Operational Excellence at Carlsmed.
With more than 30 years of experience in the medical device industry, Jeff has held leadership roles across Operations, Information Technology, Sales Operations, and corporate strategy. Prior to joining Carlsmed, he served in key positions at U.S. Surgical Corporation, SpineWave, and NuVasive.
Jeff completed the Chief Technology Officer (CTO) Program at the Wharton School of the University of Pennsylvania. He holds an MBA from Rensselaer Polytechnic Institute and a Bachelor of Science in Operations and Materials Management from Arizona State University.

Niall Casey
Chief Intellectual Property Officer
Niall Casey
Chief Intellectual Property Officer
Niall is the co-founder and Chief Intellectual Property Officer at Carlsmed and serves as Secretary on the Board of Directors.
A seasoned professional in the spine industry, Niall brings deep expertise in technology leadership and intellectual property strategy. He has held key roles at leading medical device companies including Alphatec Spine, Ellipse Technologies, NuVasive, and J&J’s DePuy Synthes Spine.
Niall holds a J.D. from Suffolk University, as well as an M.S. and B.S. in Biomedical Engineering from Case Western Reserve University.

Scott Durall
Chief Commercial Officer
Scott Durall
Chief Commercial Officer
Scott is the Chief Commercial Officer at Carlsmed.
With more than 30 years of experience in the medical device industry, Scott has held leadership roles across sales, marketing, and corporate strategy. His career includes successful tenures at U.S. Surgical Corporation, Boston Scientific Corporation, and NuVasive.
Scott holds a Bachelor of Business Administration in Marketing from the University of Kentucky.

Leo Greenstein
Chief Financial Officer
Leo Greenstein
Chief Financial Officer
Leo is the Chief Financial Officer at Carlsmed.
Leo has over two decades of experience in business and finance. He has garnered expertise in the surgical device, pharmaceutical, and oncology diagnostics sectors. His leadership journey includes significant roles at prominent companies such as Spectrum Pharmaceuticals, Endologix, and most recently, Tarsus Pharmaceuticals.
Leo holds a Juris Doctor Degree from Temple University’s Beasley School of Law and Bachelor of Science Degree in Accounting from Arcadia University. He is a Certified Public Accountant and member of the California State Bar.

Shariq Hussain
Chief Technology Officer
Shariq Hussain
Chief Technology Officer
Shariq is the Chief Technology Officer at Carlsmed.
He has a strong track record of entrepreneurship and execution in technology and executive leadership roles at MedTech companies Intelliguard Solutions and Safety Syringes.
Shariq holds an MBA in Technology Management from National University, a B.S. in Computer Science and Engineering from UC San Diego, and another B.S. in Information Technology from National University.

Julie Lamothe
Vice President of Regulatory Affairs & Quality Assurance
Julie Lamothe
Vice President of Regulatory Affairs & Quality Assurance
Julie Lamothe is the Vice President of Regulatory Affairs & Quality Assurance at Carlsmed.
She brings over 15 years of experience in the medical industry, including more than a decade focused on spine technologies. Julie’s deep expertise in microbiology, industrial sterilization, and biocompatibility helps ensure the safety and compliance of Carlsmed’s products across global markets.
Julie holds a Ph.D. in Microbiology and Immunology and an MBA from the Rady School of Management at UC San Diego — a unique blend of scientific depth and strategic leadership that drives regulatory excellence at Carlsmed.

Sharon Schulzki
Chief Clinical & Market Access Officer
Sharon Schulzki
Chief Clinical & Market Access Officer
Sharon is the Chief Clinical & Market Access Officer at Carlsmed.
Sharon’s extensive professional journey includes senior leadership roles in marketing and surgical affairs at prominent companies such as J&J and Stryker. She has also played crucial C-suite roles at successful startup ventures, namely Micropore Biosurgery, N-Spine, and Tissue Regeneration Systems, all of which achieved successful exits.
Sharon holds a Bachelor of Science degree in Medical Technology from Loyola University Maryland.
Mike Cordonnier
Chief Executive Officer
Mike is the co-founder and serves as Chief Executive Officer and President of Carlsmed, he also serves as Chairman of the Board of Directors.
Mike has over two decades of experience successfully leading teams in introducing groundbreaking medical technologies. He possesses extensive operational expertise in both private and public companies, having contributed to the success of organizations such as NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems.
Mike holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.
Board of Directors
Mike is the co-founder and serves as Chief Executive Officer and President of Carlsmed, he also serves as Chairman of the Board of Directors.
Mike has over two decades of experience successfully leading teams in introducing groundbreaking medical technologies. He possesses extensive operational expertise in both private and public companies, having contributed to the success of organizations such as NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems.
Mike holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.
Niall is the co-founder and serves as Chief Intellectual Property Officer of Carlsmed and Secretary on the Board of Directors.
As a seasoned professional in the spine industry, Niall brings valuable experience from technology leadership roles at well-established companies such as Alphatec Spine, Ellipse Technologies, NuVasive, and J&J DePuy Synthes Spine.
Niall earned a J.D. from Suffolk University and an M.S. and B.S. degree in Biomedical Engineering from Case Western Reserve University.
Jon is a General Partner at U.S. Venture Partners. He serves as a Board Member at Edgewise Therapeutics, Inari Medical, Silverback Therapeutics, Cleave Therapeutics, HealthJoy, Okami Medical, Omada Health, Nuvaira, Ribon Therapeutics, Route 92 Medical and Sparrow Pharmaceuticals. Jon previously served as a Board Member at eFFECTOR Therapeutics, Lutonix, Microvention, OncoMed Pharmaceuticals, Sequent Medical and Proteolix.
Prior to U.S. Venture Partners, he was an Assistant Professor of Neurology and Director of the Neurology-Neurosurgery Special Care Unit at Cornell Medical Center.
Jon earned an M.D. from the University of Florida College of Medicine, an M.B.A. from Columbia University, and an A.B. in Economics from Dartmouth College.
Robert is a General Partner and Head of Healthcare who leads venture and growth investments at B Capital in the sector. Robert and his team have led investments in Hotspot Therapeutics, Lively, Aetion, Oncomyx, and Triumvira OR. He currently serves as a Board Director or Board Observer at Hotspot Therapeutics, Lively, Aetion, Oncomyx, and Triumvira. Previously, he served as a Board Director or Observer at Impel NeuroPharma, Silk Road Medical, TigerConnect, Avalyn Pharma, Neocis, Telcare, VisitPay, IntersectENT, iRhythm, Omada, TalkSpace, and iCardiac.
Prior to his career in venture capital, Robert led Marketing and Business Development at Hansen Medical.
Robert earned an M.D. from Harvard University, an M.B.A. from Harvard Business School, an M.S. in Systems Engineering from the Massachusetts Institute of Technology, and an M.A. in International Relations from Kings College London.
Phil serves as Senior Advisor at US Venture Partners, following 20 years as a managing general partner of the firm. He previously served as a Board Member at Aerogen, Aptus Endosystems, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, Dotomi, FemRx, HeartFlow, La Jolla Pharmaceuticals, Penederm, 3Dfx Interactive, RelayHealth, SentreHEART, Simpirica Spine, Synarc, St. Francis Medical Technologies, The Immune Response Corporation, Vical, Xoma and Zoran.
Prior to US Venture Partners, Phil was the President and CEO of Oximetrix. He also served on the Board of Trustees of Cornell University and was the Chair of eCornell for nearly 20 years.
Phil earned an M.B.A. from Harvard Business School, an M.S. in Engineering Physics from George Washington University, and a B.M.E. from Cornell University.
Kevin is a Board Member at Intrinsic Therapeutics, Miach Orthopaedics, Razor Medical, FzioMed, Shoulder Innovations, and Moximed.
He previously served on the Board at Rotation Medical, Ceterix, and Pivot Medical. Kevin is the former CEO of St. Francis Medical Technologies, Moximed, as well as past Worldwide President of Johnson & Johnson’s DePuy Orthopedics.
Kevin earned a B.S. in Accounting from West Virginia University.
Kevin is currently a Board Member at Nevro (NVRO), and previously served as a Director of seven publicly traded companies, including Wright Medical Group (WMGI), GenMark Diagnostics (GNMK) and Zeltiq (ZLTQ).
Kevin is a former Senior Vice President and CFO of Advanced BioHealing and served as CFO of NuVasive. Prior to that, he was CFO and COO at ChromaVision Medical Systems (CVSN). Kevin also held several leadership positions at Albert Fisher Group PLC, including CFO and SVP Operations.
Kevin earned a B.S. in Accounting from Rochester Institute of Technology and completed the Executive Program at the UCLA Anderson School of Management.
Paving the Way for the Future of Spinal Fusion Surgery
First company to receive FDA Breakthrough Device Designation for Intervertebral Spine Fusion Technology
2020
July
aprevo® Lumbar receives FDA Breakthrough Device Designation
December
FDA 510(k) clearance granted for aprevo® Lumbar
2021
February
First aprevo® ALIF procedure performed in a patient
June
First aprevo® LLIF procedure performed in a patient
August
First aprevo® TLIF-O procedure performed in a patient
October
aprevo® Lumbar receives CMS NTAP reimbursement and TPT payment approval
2022
August
First aprevo® TLIF-C procedure performed in a patient
October
Enrollment begins for the COMPASS™ personalized spine surgery study
2023
January
First aprevo® ALIF-X procedure performed in a patient
September
Carlsmed receives second FDA Breakthrough Device Designation for cervical technology
2024
August
First aprevo® TLIF-CA procedure performed in a patient
November
Launch of Carlsmed’s cutting-edge digital production line
December
FDA 510(k) clearance granted for aprevo® Cervical
2025
June
First aprevo® Lumbar Angled Solutions procedure performed in a patient
July
First aprevo® ACDF procedure performed in a patient
July
First aprevo® ACDF-X procedure performed in a patient
July
Carlsmed completes Initial Public Offering and begins trading on Nasdaq
August